Over Two Years of Sustained Remission With Olaparib Monotherapy in Stage IV Non-Small Cell Lung Cancer With ATM Mutation: A Case Report

Department

Internal Medicine

Document Type

Article

Publication Title

Cancer Reports (Hoboken, N.J.)

Abstract

Background: Ataxia telangiectasia mutated (ATM) mutations represent the most common homologous recombination deficiency (HRD) mutation in non-small cell lung cancer (NSCLC). However, their therapeutic role in NSCLC has not been established.

Case: Here, we present a case of a 91-year-old male with metastatic NSCLC who progressed on multiple lines of treatment. Next-generation sequencing revealed ATM mutations, leading to the initiation of olaparib, which successfully achieved remission over a two-year period.

Conclusion: This case underscores the promising role of olaparib in treating NSCLC with HRD, particularly ATM mutations, highlighting the importance of molecular testing and targeted therapies.

First Page

e70276

DOI

10.1002/cnr2.70276

Volume

8

Issue

7

Publication Date

7-1-2025

Medical Subject Headings

Humans; Male; Carcinoma, Non-Small-Cell Lung (drug therapy, genetics, pathology); Piperazines (therapeutic use, administration & dosage); Phthalazines (therapeutic use, administration & dosage); Lung Neoplasms (drug therapy, genetics, pathology); Ataxia Telangiectasia Mutated Proteins (genetics); Mutation; Aged, 80 and over; Remission Induction; Neoplasm Staging; Poly(ADP-ribose) Polymerase Inhibitors (therapeutic use); Treatment Outcome

PubMed ID

40622001

Link to Full Text

Share

COinS